jueves, 18 de septiembre de 2014

ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort

ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort

Univadis - un servicio de MSD

American Academy of Neurology

ABO blood type, factor VIII, 

and incident cognitive 

impairment in the REGARDS 


  1. Mary Cushman, MD, MSc
  1. Correspondence to Dr. Cushman: mary.cushman@uvm.edu
  1. Neurology10.1212/WNL.0000000000000844


    Objective: To assess the relationships among ABO group, factor VIII (FVIII),
    and incident cognitive impairment in a large, prospective cohort study of
    black and white adults in the United States using a nested case-control design.
    Methods: Incident cognitive impairment was defined using cognitive domain
    tests over a mean follow-up of 3.4 years. ABO blood group was measured by
    genotyping in a nested case-control sample of 495 cases with cognitive
    impairment and 587 controls.
    Results: Those with blood group AB and those with higher FVIII had an
    increased risk of cognitive impairment, adjusting for age, race, region, and
    sex (respective odds ratios 1.82, 95% confidence interval [CI] 1.15–2.90;
    and 1.24, 95% CI 1.10–1.38 for 40 IU/dL higher FVIII). Mean FVIII was
    higher in those with blood type AB (142 IU/dL; 95% CI 119–165) compared
    with O (104 IU/dL; 95% CI 101–107), and FVIII mediated 18% of the
    association between AB group and incident cognitive impairment
    (95% CI for mediation −30% to 68%).
    Conclusions: Blood group AB and higher FVIII were associated
    with increased incidence of cognitive impairment in this prospective
    study. The association of blood group AB with incident cognitive
    impairment was not significantly mediated by FVIII levels.
    • Received April 17, 2014.
    • Accepted in final form July 3, 2014.

    No hay comentarios:

    Publicar un comentario